issues
May 2010
Download PDFTABLE OF CONTENTS
Amino Acid-Containing Degradable Polymers & Their Potential in Controlled Drug Delivery
Aylvin A. Dias, PhD, MSc, and Marc Hendriks, PhD, MBA, indicate it is worthwhile evaluating both chemically degradable and enzymatically biodegradable polymers and scrutinize the in vitro and in vivo testing results to define the optimal system in the design of degradable polymer-based drug delivery systems.
United We Stand: the Power of Alliances in the New
Derek G. Hennecke, MBA, continues with part 2 of this 6-part series on business models and best practices for navigating the new normal.
Drug Delivery Products & Technologies, a Decade in Review: Approved Products 2000 to 2009
Josef Bossart, PhD; Kurt Sedo; and Tugrul T. Kararli, PhD, MBA; review what Drug Delivery has “delivered” in the past decade. An important perspective is provided by looking at drug delivery products approved by the FDA in the past decade.
In Vivo Delivery of Nucleic Acid-Based Agents With Electroporation
Karen E. Dolter, PhD; Claire F. Evans, PhD; and Drew Hannaman believe in vivo EP is a robust, adaptable method for achieving 10- to 1000-fold enhancement in DNA uptake and expression in a variety of tissue types, and as such, may be able to overcome the suboptimal clinical potency observed with conventionally administered nucleic acid drugs.
Topical Delivery of Hydrophobic Drugs Using a Novel Mixed Nanomicellar Technology to Treat Diseases of the Anterior & Posterior Segments of the Eye
Poonam R. Velagaleti, PhD; Eddy Anglade, MD; I. John Khan, PhD; Brian C. Gilger, DVM; and Ashim K. Mitra, PhD; suggest this unique nanomicellar drug delivery platform presents potential opportunities for topical administration of additional hydrophobic drugs and the ability to non-invasively target retinal and other posterior segment diseases.
Incorporating Sorbents Into Drug Delivery Technology
Adrian Possumato says it is becoming increasingly important for manufacturers to incorporate sorbent technology much earlier in the product development and design process than has previously been the case.
The Importance of Incorporating Aesthetics Into Topical Formulations
Gary Watkins, MS, emphasizes that for a skin care product to be successful, its sensory characteristics must be specifically developed and produced in a way that appeals to the end users.
Performance Excipients: Finding a Role in the Pharmaceutical Future
Drug Delivery Executive: Herman Mitchell, Director of Global Marketing for Mallinckrodt Baker, talks about his company’s unique performance excipient brand and its role in future pharmaceutical technology.
Merrion Pharmaceuticals: Validating Oral Delivery
Drug Delivery Executive: John Lynch, CEO of Merrion, discusses how his company’s partnership with Novo Nordisk to develop both oral insulin and an oral GLP-1 analogue has helped validate its technology among the pharma community.
Non-ATP Competitive Kinase-Signaling Inhibitors & Oncology Drug Discovery & Development
Allen Barnett, PhD, examines the design of potent (low nanomolar range) and selective Src-signaling inhibitors and identifies two potential clinical development candidates, attesting to the power of the technology platform.
Invetech: Creating Innovative Products That Redefine Markets
Executive Summary: Andreas Knaack, Director of the Biomedical Instruments & Devices division at Invetech, discusses how the company is working with customers to redefine their market with breakthrough and innovative product design, development, and manufacture.
Meeting the Challenges of Antimicrobial Resistance
Ron Najafi, PhD, suggests locally administered non-antibiotic anti-infectives, such as NovaBay’s Aganocide compounds, may be much more appropriate than antibiotics in situations where the infection or colonization is accessible and not yet systemic
DEPARTMENTS
Market News & Trends
Advanced Delivery Devices
The AdminPenTM Microneedle Device for Painless & Convenient
Drug Delivery
Technology Showcase
COVER
FEATURES
